13
2023-09
唯久生物NLRP3抑制剂IND获美国FDA批准，即将启动I期临床研究，进一步加强新药管线的全球布局
唯久生物技术（苏州）有限公司（以下简称“唯久生物”）近日宣布公司自主研发的口服小分子NLRP3抑制剂成功获得FDA临床试验许可，并将于近期开展美国I期临床首次人体给药。这是公司继2022年推进临床研究的GPCR拮抗剂后的又一重大里程碑，充分体现了公司团队强大的专业能力、研发效率及项目推进执行力。
14
2022-06
Viva Star Biosciences recently announced that it has completed a Series A financing round of tens of millions of USD. The funds raised will be used to rapidly advance the IND filing and clinical trials of the company's first-in-class new drug program, accelerate product pipeline layout and implementation
